Successful antiviral treatment for fulminant reactivated hepatitis B after autologous stem cell transplantation and prophylaxis during subsequent allogeneic stem cell transplantation.

Abstract

The risk of severe hepatic damage due to reactivation of hepatitis B virus (HBV) infection after intensive myelosuppressive chemotherapy is well known. Two of the most evolved nucleotide analogues showing good activity against the hepatitis B virus are lamivudine and famciclovir. We report the successful therapeutic use of lamivudine and famciclovir for fulminant reactivated hepatitis B after autologous peripheral blood stem cell transplantation (PBSCT) and the subsequent prophylactic use of lamivudine during allogeneic blood stem cell transplantation (alloSCT) for chronic lymphocytic leukemia (CLL) in a 40-year-old patient. Antiviral therapy was well tolerated and no hematotoxicity occurred. Our observation warrants further investigation of antiviral therapy with famciclovir and lamivudine in HBV carriers receiving intensive myelosuppressive chemotherapy.

• Authors: M Henkes, S Martin, H Einsele, W E Aulitzky
• Journal: Annals of hematology (Ann Hematol) Vol. 81 Issue 6 Pg. 343-6 (Jun 2002) ISSN: 0939-5555 [Print] Germany
• PMID: 12107567 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antiviral Agents
• Lamivudine
• 2-Aminopurine
• Famciclovir

Topics

• 2-Aminopurine (analogs & derivatives, therapeutic use)
• Adult
• Antiviral Agents (therapeutic use)
• Famciclovir
• Female
• Hematopoietic Stem Cell Transplantation
• Hepatitis B (drug therapy, prevention & control)
• Hepatitis B virus (growth & development)
• Humans
• Lamivudine (therapeutic use)
• Transplantation, Autologous
• Transplantation, Homologous
• Virus Activation